Portal vein thrombosis (PVT) happens when a blood clot forms in the portal vein, the major vessel that carries blood from your digestive organs to your liver. It affects an estimated 2 to 4 people per 100,000 each year in the general population, but it’s far more common in people with liver disease or blood disorders. The causes fall into a few major categories: liver cirrhosis, cancer, blood clotting disorders, abdominal infections, surgery, and hormonal factors.
How a Clot Forms in the Portal Vein
Clots in the portal vein develop through the same basic mechanism as clots elsewhere in the body. Three conditions work together: sluggish blood flow, damage to the vessel wall, and blood that clots too easily. In the portal vein system, all three of these conditions can arise from different underlying diseases, and they often overlap. Someone with cirrhosis, for example, may have slow portal blood flow and abnormal clotting at the same time.
When a clot blocks the portal vein, it can be classified as recent (present for less than six months) or chronic (persisting beyond six months). In chronic cases, the body tries to reroute blood around the blockage. Small collateral vessels can begin forming as early as 12 days after the clot appears, with the average time to development around five weeks. Over time, these vessels can grow into a tangle of small channels called a portal cavernoma, which partially compensates for the blocked vein but doesn’t fully restore normal blood flow.
Liver Cirrhosis
Cirrhosis is the single most common cause of portal vein thrombosis. Roughly 10 to 25% of people with cirrhosis will eventually develop a clot in the portal vein, and one study found a prevalence of 17.2% among cirrhotic patients. The risk increases as liver disease worsens.
Several things about cirrhosis make the portal vein vulnerable. The scarred liver tissue physically resists blood flow, which slows the speed of blood moving through the portal vein. That sluggish flow gives clots more opportunity to form. At the same time, cirrhosis disrupts the liver’s production of both clotting and anti-clotting proteins, creating an unpredictable imbalance that can tip toward excessive clotting. The combination of stagnant flow and disordered coagulation makes the portal vein a prime target.
Liver Cancer and Other Malignancies
Hepatocellular carcinoma, the most common type of primary liver cancer, has a particularly strong link to portal vein thrombosis. Between 10% and 40% of people with hepatocellular carcinoma already have PVT at the time of diagnosis, and 35 to 44% will have it by the time of death or liver transplant. In some cases, the clot is actually tumor tissue invading the portal vein rather than a standard blood clot, which changes both the prognosis and the treatment approach.
Other abdominal cancers, especially pancreatic cancer, can also cause PVT. Tumors may compress or invade the portal vein directly, or they may push the body into a hypercoagulable state where blood clots form more readily throughout the venous system.
Blood Clotting Disorders
In people without cirrhosis or cancer, inherited or acquired clotting disorders are a leading cause of PVT. These conditions make the blood clot too aggressively, and the portal vein’s relatively slow flow makes it especially susceptible.
Myeloproliferative neoplasms are among the most important of these. These are a group of blood cancers in which the bone marrow overproduces blood cells, including conditions like polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Many of these disorders carry a specific genetic mutation called JAK2 V617F. People with this mutation alone have roughly double the risk of thrombotic events, but those who also carry a second inherited clotting mutation called Factor V Leiden face a risk roughly four times higher than people without either mutation.
Factor V Leiden on its own is one of the most common inherited clotting abnormalities. It makes a key clotting protein resistant to being switched off by the body’s natural anticoagulant system. Other inherited conditions that raise the risk include deficiencies in proteins that normally prevent excessive clotting, such as protein C, protein S, and antithrombin.
Abdominal Infections and Inflammation
Infections or inflammatory conditions inside the abdomen can trigger a specific form of portal vein thrombosis called pylephlebitis, which is essentially an infected clot. This happens when bacteria from an abdominal infection spread through local veins that drain into the portal system, causing inflammation and clotting along the way.
The most common trigger is diverticulitis, which accounts for about 28% of pylephlebitis cases. Appendicitis and pancreatitis are also frequent culprits. E. coli, a bacterium that normally lives in the gut, is the most commonly identified pathogen, which makes sense given that the infections typically originate in the digestive tract. Pylephlebitis is uncommon overall, but it’s a serious diagnosis because it combines the risks of both infection and vascular obstruction.
Surgery and Procedures
Abdominal surgery, particularly operations near the portal vein, can trigger clot formation through direct vessel injury and the temporary changes in blood flow that follow any major procedure. Splenectomy (removal of the spleen) is a well-known risk factor because the splenic vein feeds directly into the portal vein, and removing the spleen alters both flow dynamics and platelet counts.
After liver transplantation, portal vein thrombosis occurs in about 1 to 2% of cases. Though the incidence is low, it’s a serious complication that can threaten the transplanted organ. Other hepatobiliary surgeries, including procedures on the bile ducts or pancreas, can also increase risk due to their proximity to the portal venous system.
Hormonal and Reproductive Factors
Estrogen-containing hormonal contraceptives increase the risk of blood clots throughout the venous system, including the portal vein. Women using hormonal contraception are approximately four times more likely to develop thromboembolism compared to women not using it. Estrogen raises levels of several pro-clotting proteins in the blood while simultaneously lowering levels of natural anticoagulants, shifting the balance toward clot formation.
Pregnancy creates a similar hormonal environment, with elevated estrogen levels and additional physical changes that slow venous blood flow. In younger patients without liver disease, the combination of hormonal contraceptive use with an undiagnosed inherited clotting disorder is a particularly important pattern. Someone might carry Factor V Leiden without knowing it and only develop a clot when estrogen exposure tips the balance.
When No Clear Cause Is Found
Even after thorough testing, some cases of portal vein thrombosis remain unexplained. These are sometimes labeled idiopathic. However, as screening for genetic clotting mutations and myeloproliferative neoplasms has improved, the proportion of truly unexplained cases has decreased. If you’re diagnosed with PVT without an obvious cause like cirrhosis or cancer, testing for inherited thrombophilias and the JAK2 mutation is a standard part of the workup, since identifying the underlying driver changes how the clot is managed long-term.